Respiratory redux

Experienced entrepreneurs, deep-pocketed investors and assets with best-in-class potential drove SR One’s participation in inhaled infectious disease company Pulmocide Ltd.’s series B round last week.

SR One led the $30.4 million round, which saw participation from fellow new investor Longwood Fund and existing investors SV Life Sciences, F-Prime Capital, the Johnson & Johnson Innovation-JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ) and Touchstone Innovations plc (LSE:IVO). ...